Abstract: Flow cytometry (FCM) is more sensitive than conventional cytology for detection of occult leptomeningeal lymphoma; however, some FCM-negative patients show central nervous system (CNS) recurrence.
New interim analysis study findings presented for the first time today at the 55th American Society of Hematology (ASH) Annual Meeting in New Orleans suggest bendamustine and rituximab… read more.
Our defences against infection can be weaknesses in causing cancer. Scientists have discovered a genetic signature that implicates a key mechanism in the immune system as a driving… read more.
by Bruce Sylvester – While early stem cell transplantation in patients with aggressive non-Hodgkin’s lymphoma does not improve overall survival in intermediate/high-risk patients, early transplantation appears to be… read more.
by Bruce Sylvester – While early stem cell transplantation in patients with aggressive non-Hodgkin’s lymphoma does not improve overall survival in intermediate/high-risk patients, early transplantation appears to be… read more.
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
FDA Highlights by Bruce Sylvester – Researchers report from a phase I clinical trial report that diffuse, large B-cell lymphomas (DLBCLs) resistant to chemotherapy have been successfully reprogrammed… read more.
Matthias Holdhoff, MD, PHD, Assistant Professor of Oncology. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr Brian Healey Bird FCPI. Consultant Medical Oncologist, Bon Secours Cork. Senior Clinical Lecturer, University College Cork.
by Elizabeth C. Smyth, MB, BCh, MSc, and David Cunningham, MD, FRCP, FMedSci – In 2000, in order to optimise service provision for patients with cancer, 34 “Cancer… read more.
Doctors should use different therapies when treating older and younger patients with chronic lymphocytic leukemia, according to a new study.
Researchers reported encouraging but preliminary results of gene-based immune therapy in two children with relapsed and refractory acute lymphoblastic leukemia (ALL).
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
